Company profile for Acrotech Biopharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Founded in 2018, Acrotech Biopharma LLC, was formed as a global platform to commercialize innovative proprietary medications. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. Acrotech aspires to be a patient focused, research-based organization that strives to launch treatments which are accessible to patients that need them...
Founded in 2018, Acrotech Biopharma LLC, was formed as a global platform to commercialize innovative proprietary medications. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. Acrotech aspires to be a patient focused, research-based organization that strives to launch treatments which are accessible to patients that need them. We put our passion to work for healthier communities around the world. Our Social Impact Report shares details on how we’re doing it—this includes providing affordable medicines, collaborating with patient groups

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
279 Princeton Hightstown Rd., East Windsor, NJ 08520 (866) 850-2876
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/casi-pharmaceuticals-provides-business-and-clinical-update-1028949

ACCESSWIRE
19 May 2025

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/casi-pharmaceuticals-enters-into-definitive-agreement-for-the-divesti-1026311

ACCESSWIRE
12 May 2025

https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-urges-acrotech-speed-up-study-cancer-drugs-2023-11-16/

REUTERS
16 Nov 2023

https://www.indianpharmapost.com/news/evive-enters-license-agreement-with-acrotech-biopharma-to-commercialize-ryzneuta-in-us-13335

INDIANPHARMAPOST
24 Nov 2022

https://endpts.com/fdas-cancer-drug-advisors-will-review-2-more-dangling-accelerated-approvals-for-multiple-myeloma-leukemia/

Z. Brennan ENDPTS
24 Sep 2021

https://www.businesswire.com/news/home/20210426005126/en/Acrotech-Biopharma-Announces-the-Publication-of-Data-From-a-Phase-1-Study-of-BELEODAQ%C2%AE-belinostat-Combined-With-Standard-CHOP-Bel-CHOP-in-Patients-With-Previously-Untreated-Peripheral-T-cell-Lymphoma

BUSINESSWIRE
26 Apr 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty